Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1180 participants.

Also called NCT05700266

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 1,180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05700266
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05700266. Randomized; single masking; primary purpose prevention. Start 2023-12-30 (anticipated); primary completion 2024-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
Acronym
AA-ICAS
Condition
Intracranial Atherosclerosis
Condition
Stenosis
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Aspirin
Intervention (Other)
Risk Factor Management in both arms
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University (class: other)
Collaborator
National Natural Science Foundation of China (class: other government)

Record details

Record id
cardio:ct-nct05700266
Content hash
4ace47aee213b24a569768960638c689f47d21e24cbc79813b7ffbb39508d1e4